NEW DELHI: MicrobioTx has introduced a new predictive solution—IBS Risk Score—aimed at assessing an individual’s likelihood of developing Irritable Bowel Syndrome (IBS), marking IBS Awareness Month in April.

IBS remains one of India’s most common yet underdiagnosed gastrointestinal conditions, affecting an estimated 4–8% of the population, or nearly 40–80 million people. The absence of a definitive diagnostic test often results in delayed detection, misdiagnosis, and prolonged discomfort for patients experiencing symptoms such as abdominal pain, bloating, and irregular bowel habits.

MicrobioTx’s IBS Risk Score leverages advanced gut microbiome profiling combined with metabolite analysis—biological markers released by microbes into the bloodstream—to identify patterns associated with IBS. The tool is designed to enable early risk detection and support more informed clinical decision-making.

The solution builds on the company’s recent clinical study conducted in collaboration with Maulana Azad Medical College, which validated the effectiveness of its Gut Function Test (GFT) in identifying microbiome imbalances specific to Indian IBS patients.

According to Dr Ujjwal Sonika, gut dysbiosis plays a key role in the development of IBS and presents a potential avenue for therapeutic intervention.

By shifting the focus from reactive diagnosis to proactive risk assessment, the new IBS Risk Score aims to improve early detection and patient outcomes. The launch underscores MicrobioTx’s continued push toward accessible, science-backed innovations in microbiome-based healthcare.